Advanced search
1 file | 347.15 KB Add to list

Long-term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in oligometastatic prostate cancer : analysis of STOMP and ORIOLE trials

(2022) JOURNAL OF CLINICAL ONCOLOGY. 40(29). p.3377-3382
Author
Organization
Abstract
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. The initial STOMP and ORIOLE trial reports suggested that metastasis-directed therapy (MDT) in oligometastatic castration-sensitive prostate cancer (omCSPC) was associated with improved treatment outcomes. Here, we present long-term outcomes of MDT in omCSPC by pooling STOMP and ORIOLE and assess the ability of a high-risk mutational signature to risk stratify outcomes after MDT. The primary end point was progression-free survival (PFS) calculated using the Kaplan-Meier method. High-risk mutations were defined as pathogenic somatic mutations within ATM, BRCA1/2, Rb1, or TP53. The median follow-up for the whole group was 52.5 months. Median PFS was prolonged with MDT compared with observation (pooled hazard ratio [HR], 0.44; 95% CI, 0.29 to 0.66; P value < .001), with the largest benefit of MDT in patients with a high-risk mutation (HR high-risk, 0.05; HR no high-risk, 0.42; P value for interaction: .12). Within the MDT cohort, the PFS was 13.4 months in those without a high-risk mutation, compared with 7.5 months in those with a high-risk mutation (HR, 0.53; 95% CI, 0.25 to 1.11; P = .09). Long-term outcomes from the only two randomized trials in omCSPC suggest a sustained clinical benefit to MDT over observation. A high-risk mutational signature may help risk stratify treatment outcomes after MDT.
Keywords
STEREOTACTIC BODY RADIOTHERAPY

Downloads

  • MW.pdf
    • full text (Published version)
    • |
    • open access
    • |
    • PDF
    • |
    • 347.15 KB

Citation

Please use this url to cite or link to this publication:

MLA
Deek, MP, et al. “Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy versus Observation in Oligometastatic Prostate Cancer : Analysis of STOMP and ORIOLE Trials.” JOURNAL OF CLINICAL ONCOLOGY, vol. 40, no. 29, 2022, pp. 3377–82, doi:10.1200/JCO.22.00644.
APA
Deek, M., Van der Eecken, K., Sutera, P., Deek, R., Fonteyne, V., Mendes, A., … Tran, P. (2022). Long-term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in oligometastatic prostate cancer : analysis of STOMP and ORIOLE trials. JOURNAL OF CLINICAL ONCOLOGY, 40(29), 3377–3382. https://doi.org/10.1200/JCO.22.00644
Chicago author-date
Deek, MP, K Van der Eecken, P Sutera, RA Deek, Valerie Fonteyne, AA Mendes, Karel Decaestecker, et al. 2022. “Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy versus Observation in Oligometastatic Prostate Cancer : Analysis of STOMP and ORIOLE Trials.” JOURNAL OF CLINICAL ONCOLOGY 40 (29): 3377–82. https://doi.org/10.1200/JCO.22.00644.
Chicago author-date (all authors)
Deek, MP, K Van der Eecken, P Sutera, RA Deek, Valerie Fonteyne, AA Mendes, Karel Decaestecker, AP Kiess, Nicolaas Lumen, R Phillips, Aurélie De Bruycker, M Mishra, Z Rana, J Molitoris, Bieke Lambert, Louke Delrue, H Wang, K Lowe, Sofie Verbeke, Jo Van Dorpe, Renée Bultijnck, Geert Villeirs, Kathia De Man, F Ameye, DY Song, T DeWeese, CJ Paller, FY Feng, A Wyatt, KJ Pienta, M Diehn, SM Bentzen, S Joniau, F Vanhaverbeke, G De Meerleer, ES Antonarakis, TL Lotan, A Berlin, S Siva, Piet Ost, and PT Tran. 2022. “Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy versus Observation in Oligometastatic Prostate Cancer : Analysis of STOMP and ORIOLE Trials.” JOURNAL OF CLINICAL ONCOLOGY 40 (29): 3377–3382. doi:10.1200/JCO.22.00644.
Vancouver
1.
Deek M, Van der Eecken K, Sutera P, Deek R, Fonteyne V, Mendes A, et al. Long-term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in oligometastatic prostate cancer : analysis of STOMP and ORIOLE trials. JOURNAL OF CLINICAL ONCOLOGY. 2022;40(29):3377–82.
IEEE
[1]
M. Deek et al., “Long-term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in oligometastatic prostate cancer : analysis of STOMP and ORIOLE trials,” JOURNAL OF CLINICAL ONCOLOGY, vol. 40, no. 29, pp. 3377–3382, 2022.
@article{8767914,
  abstract     = {{Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. The initial STOMP and ORIOLE trial reports suggested that metastasis-directed therapy (MDT) in oligometastatic castration-sensitive prostate cancer (omCSPC) was associated with improved treatment outcomes. Here, we present long-term outcomes of MDT in omCSPC by pooling STOMP and ORIOLE and assess the ability of a high-risk mutational signature to risk stratify outcomes after MDT. The primary end point was progression-free survival (PFS) calculated using the Kaplan-Meier method. High-risk mutations were defined as pathogenic somatic mutations within ATM, BRCA1/2, Rb1, or TP53. The median follow-up for the whole group was 52.5 months. Median PFS was prolonged with MDT compared with observation (pooled hazard ratio [HR], 0.44; 95% CI, 0.29 to 0.66; P value < .001), with the largest benefit of MDT in patients with a high-risk mutation (HR high-risk, 0.05; HR no high-risk, 0.42; P value for interaction: .12). Within the MDT cohort, the PFS was 13.4 months in those without a high-risk mutation, compared with 7.5 months in those with a high-risk mutation (HR, 0.53; 95% CI, 0.25 to 1.11; P = .09). Long-term outcomes from the only two randomized trials in omCSPC suggest a sustained clinical benefit to MDT over observation. A high-risk mutational signature may help risk stratify treatment outcomes after MDT.}},
  author       = {{Deek, MP and Van der Eecken, K and Sutera, P and Deek, RA and Fonteyne, Valerie and Mendes, AA and Decaestecker, Karel and Kiess, AP and Lumen, Nicolaas and Phillips, R and De Bruycker, Aurélie and Mishra, M and Rana, Z and Molitoris, J and Lambert, Bieke and Delrue, Louke and Wang, H and Lowe, K and Verbeke, Sofie and Van Dorpe, Jo and Bultijnck, Renée and Villeirs, Geert and De Man, Kathia and Ameye, F and Song, DY and DeWeese, T and Paller, CJ and Feng, FY and Wyatt, A and Pienta, KJ and Diehn, M and Bentzen, SM and Joniau, S and Vanhaverbeke, F and De Meerleer, G and Antonarakis, ES and Lotan, TL and Berlin, A and Siva, S and Ost, Piet and Tran, PT}},
  issn         = {{0732-183X}},
  journal      = {{JOURNAL OF CLINICAL ONCOLOGY}},
  keywords     = {{STEREOTACTIC BODY RADIOTHERAPY}},
  language     = {{eng}},
  number       = {{29}},
  pages        = {{3377--3382}},
  title        = {{Long-term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in oligometastatic prostate cancer : analysis of STOMP and ORIOLE trials}},
  url          = {{http://doi.org/10.1200/JCO.22.00644}},
  volume       = {{40}},
  year         = {{2022}},
}

Altmetric
View in Altmetric
Web of Science
Times cited: